Skip to main content

Table 2 Prescription of non-insulin diabetes medication by drug class for patients with T2D and average eGFR < 60mlk/min/1.73m2

From: Prescribing of diabetes medications to people with type 2 diabetes and chronic kidney disease: a national cross-sectional study

Medication Class

n (%) patients prescribed medication

n (%) of patients prescribed medication that is not consistent with dosing recommendations in ADS dosing guidelines

eGFR < 60 ml/min/1.73m2

n = 3505 patients

eGFR 45–59 ml/min/1.73m2

n = 1909 patients

eGFR 30–44 ml/min/1.73m2

n = 1261 patients

eGFR < 30 ml/min/1.73m2

n = 335 patients

Biguanide (metformin)

2853 (81.4)

1601 (58.1)

702 (25.5)

762 (27.7)

137 (5.0)

Sulphonylureas

1818 (51.9)

278 (16.0)

112 (6.5)

66 (3.8)

100 (5.8)

DPP4 inhibitorsa

1371 (39.1)

611 (46.4)

374 (28.4)

174 (13.2)

63 (4.8)

Thiazolidinediones (TZDs)

106 (3.0)

< 5

0

0

< 5

Incretin mimetics

150 (4.3)

12 (13.6)

< 5

< 5

6 (6.8)

SGLT2 inhibitorsb

218 (6.2)

180 (82.6)

125 (57.3)

51 (23.4)

< 5

Acarbose

24 (0.7)

< 5

< 5

0

< 5

Combination products (2 or more medications in a single formulation)c

Biguanide & Sulfonylureas

34 (1.0)

31 (93.9)

23 (69.7)

8 (24.2)

< 5

Biguanide & DPP4 inhibitors

574 (16.4)

475 (84.1)

286 (50.6)

156 (27.6)

33 (5.9)

Biguanide & TZDs

< 5

< 5

< 5

< 5

0

Biguanide & SGLT2 inhibitors

54 (1.5)

47 (94)

36 (72.0)

11 (22.0)

0

  1. a Dipeptidyl peptidase 4 inhibitors
  2. b Sodium glucose co-transporter 2 inhibitors
  3. cMedications included in the combination products are also included in the single medication classes above
  4. Note: cell counts less than 5 suppressed